KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Revenue: 2009-2025

Historic Revenue for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $70.4 million.

  • Novavax's Revenue fell 16.64% to $70.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 13.02%. This contributed to the annual value of $682.2 million for FY2024, which is 30.65% down from last year.
  • Novavax's Revenue amounted to $70.4 million in Q3 2025, which was down 59.75% from $175.0 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Revenue ranged from a high of $734.6 million in Q3 2022 and a low of $70.4 million during Q3 2025.
  • For the 3-year period, Novavax's Revenue averaged around $234.4 million, with its median value being $175.0 million (2025).
  • In the last 5 years, Novavax's Revenue surged by 13,143.38% in 2021 and then crashed by 88.50% in 2023.
  • Novavax's Revenue (Quarterly) stood at $222.2 million in 2021, then spiked by 60.85% to $357.4 million in 2022, then declined by 18.48% to $291.3 million in 2023, then slumped by 69.69% to $88.3 million in 2024, then declined by 16.64% to $70.4 million in 2025.
  • Its Revenue was $70.4 million in Q3 2025, compared to $175.0 million in Q2 2025 and $666.7 million in Q1 2025.